Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood protein clue in teen PCOS mystery

NCT ID NCT07480993

Knowledge-focused Sponsor: Ankara City Hospital Bilkent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study measured levels of a protein called betatrophin in 90 adolescent girls with and without PCOS. Researchers wanted to see if betatrophin is linked to insulin resistance and body weight in PCOS. The goal was to better understand the metabolic problems that often come with PCOS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

90 people

The number who actually took part.

Started

Jan 2026

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population includes a total of 90 participants. The study cohort comprised 30 participants with a BMI ≥25 kg/m² (Group I) and 30 participants with a BMI \<25 kg/m² (Group II), all fulfilling the Rotterdam criteria for polycystic ovary syndrome (PCOS), in addition to 30 age-matched healthy controls (Group III).

Ages

16 to 23 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adolescent females aged 16-23 years * Post-menarche status * Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam criteria (for Groups I and II) * Age-matched healthy females without PCOS for control group (Group III). * Ability and willingness to provide informed consent/assent * Willingness to comply with study procedures and blood sample collection Exclusion Criteria: * Cardiovascular diseases including hypertension * Type 1 or type 2 diabetes mellitus * Morbid obesity * Primary adrenal insufficiency * Uterine fibroids * Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease * Hepatic dysfunctions * Renal insufficiency * Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9 * Neurologic diseases * Psychiatric disorders * Autoimmune diseases or syndromes including Addison's disease, autoimmune syndromes, scleroderma, Sjogren's syndrome, myasthenia gravis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and familial Mediterranean fever * History of any malignancy * History of exposure to chemotherapeutic agents or radiotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Betatrophin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Betatrophin Body mass index (BMI) Insulin resistance Polycystic ovary syndrome (PCOS)

Contacts and locations

Locations

  • Ankara Bilkent City Hospital

    Ankara, Not Valid, 06100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.